Cargando…

Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin

OBJECTIVES: Idiopathic inflammatory myopathies are mainly defined by inflammatory infiltrates within the muscle (lymphocytes and macrophages). Eosinophil muscle infiltration has been described in idiopathic eosinophilic myositis (IEM) and rarely in EF. This study aimed to further delineate the nosol...

Descripción completa

Detalles Bibliográficos
Autores principales: Fermon, Cécile, Lessard, Lola E R, Fenouil, Tanguy, Meyer, Alain, Faruch-Bilfeld, Marie, Robert, Marie, Landel, Verena, Hot, Arnaud, Authier, François-Jérôme, Streichenberger, Nathalie, Gallay, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234208/
https://www.ncbi.nlm.nih.gov/pubmed/36200845
http://dx.doi.org/10.1093/rheumatology/keac556
_version_ 1785052435363921920
author Fermon, Cécile
Lessard, Lola E R
Fenouil, Tanguy
Meyer, Alain
Faruch-Bilfeld, Marie
Robert, Marie
Landel, Verena
Hot, Arnaud
Authier, François-Jérôme
Streichenberger, Nathalie
Gallay, Laure
author_facet Fermon, Cécile
Lessard, Lola E R
Fenouil, Tanguy
Meyer, Alain
Faruch-Bilfeld, Marie
Robert, Marie
Landel, Verena
Hot, Arnaud
Authier, François-Jérôme
Streichenberger, Nathalie
Gallay, Laure
author_sort Fermon, Cécile
collection PubMed
description OBJECTIVES: Idiopathic inflammatory myopathies are mainly defined by inflammatory infiltrates within the muscle (lymphocytes and macrophages). Eosinophil muscle infiltration has been described in idiopathic eosinophilic myositis (IEM) and rarely in EF. This study aimed to further delineate the nosological frame of idiopathic eosinophil muscle infiltration through the exhaustive analysis of IEM and EF patients. METHODS: This multicentre retrospective case series included IEM patients diagnosed between 2000 and 2022. IEM inclusion criteria were eosinophilic muscle infiltration with myositis pathological features, after the exclusion of differential diagnoses. An additional group of EF patients diagnosed between 2016 and 2022 was constituted. Inclusion criteria were an EF diagnosis and fascia thickening with inflammatory infiltrate. RESULTS: A total of 20 IEM cases and 10 EF cases were included. The median (interquartile range) age at diagnosis was 65 (49–70) years; there were 18 males. Data analysis delineated four subgroups: focal EM (FEM, n = 3), diffuse EM (DEM, n = 6), eosinophilic myofasciitis (EMF, n = 11) and EF (n = 10). FEM represented a limited and benign form of myositis. DEM cases presented objective muscle impairment with eosinophilic muscle infiltration. EMF patients presented subjective muscle impairment (myalgia, 55%), fasciitis (on histology and/or imaging), eosinophilic muscle infiltration and frequent hypereosinophilia (55%). EF patients presented myalgia (50%), muscle lesions on histology with fascia-restricted inflammatory infiltrates with (60%) or without (40%) eosinophils. CONCLUSIONS: The analysis of IEM and EF patient characteristics delineates four subgroups (FEM, DEM, EMF and EF) in terms of clinical, laboratory, imaging, pathological and outcome specificities, and proposes an adapted diagnostic and care management approach.
format Online
Article
Text
id pubmed-10234208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102342082023-06-02 Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin Fermon, Cécile Lessard, Lola E R Fenouil, Tanguy Meyer, Alain Faruch-Bilfeld, Marie Robert, Marie Landel, Verena Hot, Arnaud Authier, François-Jérôme Streichenberger, Nathalie Gallay, Laure Rheumatology (Oxford) Clinical Science OBJECTIVES: Idiopathic inflammatory myopathies are mainly defined by inflammatory infiltrates within the muscle (lymphocytes and macrophages). Eosinophil muscle infiltration has been described in idiopathic eosinophilic myositis (IEM) and rarely in EF. This study aimed to further delineate the nosological frame of idiopathic eosinophil muscle infiltration through the exhaustive analysis of IEM and EF patients. METHODS: This multicentre retrospective case series included IEM patients diagnosed between 2000 and 2022. IEM inclusion criteria were eosinophilic muscle infiltration with myositis pathological features, after the exclusion of differential diagnoses. An additional group of EF patients diagnosed between 2016 and 2022 was constituted. Inclusion criteria were an EF diagnosis and fascia thickening with inflammatory infiltrate. RESULTS: A total of 20 IEM cases and 10 EF cases were included. The median (interquartile range) age at diagnosis was 65 (49–70) years; there were 18 males. Data analysis delineated four subgroups: focal EM (FEM, n = 3), diffuse EM (DEM, n = 6), eosinophilic myofasciitis (EMF, n = 11) and EF (n = 10). FEM represented a limited and benign form of myositis. DEM cases presented objective muscle impairment with eosinophilic muscle infiltration. EMF patients presented subjective muscle impairment (myalgia, 55%), fasciitis (on histology and/or imaging), eosinophilic muscle infiltration and frequent hypereosinophilia (55%). EF patients presented myalgia (50%), muscle lesions on histology with fascia-restricted inflammatory infiltrates with (60%) or without (40%) eosinophils. CONCLUSIONS: The analysis of IEM and EF patient characteristics delineates four subgroups (FEM, DEM, EMF and EF) in terms of clinical, laboratory, imaging, pathological and outcome specificities, and proposes an adapted diagnostic and care management approach. Oxford University Press 2022-10-06 /pmc/articles/PMC10234208/ /pubmed/36200845 http://dx.doi.org/10.1093/rheumatology/keac556 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Fermon, Cécile
Lessard, Lola E R
Fenouil, Tanguy
Meyer, Alain
Faruch-Bilfeld, Marie
Robert, Marie
Landel, Verena
Hot, Arnaud
Authier, François-Jérôme
Streichenberger, Nathalie
Gallay, Laure
Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
title Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
title_full Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
title_fullStr Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
title_full_unstemmed Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
title_short Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
title_sort revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234208/
https://www.ncbi.nlm.nih.gov/pubmed/36200845
http://dx.doi.org/10.1093/rheumatology/keac556
work_keys_str_mv AT fermoncecile revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT lessardlolaer revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT fenouiltanguy revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT meyeralain revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT faruchbilfeldmarie revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT robertmarie revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT landelverena revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT hotarnaud revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT authierfrancoisjerome revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT streichenbergernathalie revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin
AT gallaylaure revisitingidiopathiceosinophilicmyositistowardsaclinicalpathologicalcontinuumfromthemuscletothefasciaandskin